Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease.

Ravell JC, Matsuda-Lennikov M, Chauvin SD, Zou J, Biancalana M, Deeb SJ, Price S, Su HC, Notarangelo G, Jiang P, Morawski A, Kanellopoulou C, Binder KW, Mukherjee R, Anibal JT, Sellers B, Zheng L, He T, George AB, Pittaluga S, Powers A, Kleiner DE, Kapuria D, Ghany M, Hunsberger S, Cohen JI, Uzel G, Bergerson J, Wolfe L, Toro C, Gahl W, Folio LR, Matthews H, Angelus P, Chinn IK, Orange JS, Trujillo-Vargas CM, Franco JL, Orrego-Arango J, Gutiérrez-Hincapié S, Patel NC, Raymond K, Patiroglu T, Unal E, Karakukcu M, Day AG, Mehta P, Masutani E, De Ravin SS, Malech HL, Altan-Bonnet G, Rao VK, Mann M, Lenardo MJ.

J Clin Invest. 2019 Nov 5. pii: 131116. doi: 10.1172/JCI131116. [Epub ahead of print]

2.

18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.

Carrasquillo JA, Chen CC, Price S, Whatley M, Avila NA, Pittaluga S, Jaffe ES, Rao VK.

Clin Nucl Med. 2019 Oct 23. doi: 10.1097/RLU.0000000000002816. [Epub ahead of print]

PMID:
31693620
3.

18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.

Carrasquillo JA, Chen CC, Price S, Whatley M, Avila NA, Pittaluga S, Jaffe ES, Rao VK.

Clin Nucl Med. 2019 Dec;44(12):949-955. doi: 10.1097/RLU.0000000000002816.

PMID:
31689275
4.

Novel markers in pediatric-type follicular lymphoma.

Agostinelli C, Akarca AU, Ramsay A, Rizvi H, Rodriguez-Justo M, Pomplun S, Proctor I, Sabattini E, Linch D, Daw S, Pittaluga S, Pileri SA, Jaffe ES, Quintanilla-Martinez L, Marafioti T.

Virchows Arch. 2019 Nov 4. doi: 10.1007/s00428-019-02681-y. [Epub ahead of print]

PMID:
31686194
5.

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.

Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, Madan RA, Ballester LY, Pittaluga S, Donahue RN, Tsai YT, Lepone LM, Chin K, Ginty F, Sood A, Hewitt SM, Schlom J, Hassan R, Gulley JL.

J Immunother Cancer. 2019 Oct 21;7(1):269. doi: 10.1186/s40425-019-0723-9.

6.

Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology.

Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, Tyler PM, Comrie WA, Matsuda M, Olivier KN, Pittaluga S, McElwee JJ, Long Priel DA, Kuhns DB, Williams RL, Mustillo PJ, Wymann MP, Koneti Rao V, Lucas CL.

Nat Commun. 2019 Sep 25;10(1):4364. doi: 10.1038/s41467-019-12311-5.

7.

Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.

Egan C, Nicolae A, Lack J, Chung HJ, Skarshaug S, Pham TA, Navarro W, Abdullaev Z, Aguilera NS, Xi L, Pack S, Pittaluga S, Jaffe ES, Raffeld M.

Haematologica. 2019 Aug 22. pii: haematol.2019.230375. doi: 10.3324/haematol.2019.230375. [Epub ahead of print]

8.

Recurrent somatic JAK3 mutations in NK-cell enteropathy.

Xiao W, Gupta GK, Yao J, Jang YJ, Xi L, Baik J, Sigler A, Kumar A, Moskowitz AJ, Arcila ME, Raffeld M, Pittaluga S, Dogan A, Jaffe ES.

Blood. 2019 Sep 19;134(12):986-991. doi: 10.1182/blood.2019001443. Epub 2019 Aug 5. No abstract available.

PMID:
31383643
9.

ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female.

Gupta GK, Xi L, Pack SD, Jones JB, Pittaluga S, Raffeld M, Jaffe ES.

Haematologica. 2019 Nov;104(11):e534-e536. doi: 10.3324/haematol.2019.230094. Epub 2019 Aug 1. No abstract available.

10.

Image Gallery: Primary cutaneous Rosai-Dorfman disease.

Gupta GK, Pittaluga S, Cowen EW.

Br J Dermatol. 2019 Aug;181(2):e34. doi: 10.1111/bjd.17999. Epub 2019 Jun 25. No abstract available.

PMID:
31240695
11.

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.

Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

Clin Cancer Res. 2019 Aug 15;25(16):4945-4954. doi: 10.1158/1078-0432.CCR-18-3468. Epub 2019 May 29.

12.

Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites.

Cohen JI, Manoli I, Dowdell K, Krogmann TA, Tamura D, Radecki P, Bu W, Turk SP, Liepshutz K, Hornung RL, Fassihi H, Sarkany RP, Bonnycastle LL, Chines PS, Swift AJ, Myers TG, Levoska MA, DiGiovanna JJ, Collins FS, Kraemer KH, Pittaluga S, Jaffe ES.

Blood. 2019 Jun 27;133(26):2753-2764. doi: 10.1182/blood.2018893750. Epub 2019 May 7.

PMID:
31064750
13.

A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.

Gupta GK, Jaffe ES, Pittaluga S.

Histopathology. 2019 Aug;75(2):282-286. doi: 10.1111/his.13870. Epub 2019 Apr 2.

PMID:
30938862
14.

Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.

Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, Dobbs AK, Niemela JE, Stoddard J, Alhinai Z, Rybak N, Hernandez N, Pittaluga S, Rosenzweig SD, Uzel G, Notarangelo LD.

Front Immunol. 2019 Feb 14;10:77. doi: 10.3389/fimmu.2019.00077. eCollection 2019.

15.

Viral, immunologic, and clinical features of primary effusion lymphoma.

Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS.

Blood. 2019 Apr 18;133(16):1753-1761. doi: 10.1182/blood-2019-01-893339. Epub 2019 Feb 19.

16.

Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver.

Lerner AM, Bennett JE, Pittaluga S, Khil PP, Youn JH, Fahle GA, Frank KM, Dekker JP, Jerussi TD, Sun C, Wiestner A, Gea-Banacloche J.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):180-182. doi: 10.1016/j.diagmicrobio.2018.12.012. Epub 2019 Jan 2.

PMID:
30679057
17.

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2019 Aug;60(8):2062-2066. doi: 10.1080/10428194.2018.1562184. Epub 2019 Jan 10.

PMID:
30626252
18.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

19.

Lymphoid hyperplasia with atypical dendritic/Langerhans cell proliferation mimicking Hodgkin lymphoma.

Balakrishna JP, Raffeld M, Jaffe ES, Pittaluga S.

Histopathology. 2019 Apr;74(5):797-799. doi: 10.1111/his.13795. Epub 2019 Feb 13. No abstract available.

PMID:
30565719
20.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
21.

Diagnosis of Hodgkin lymphoma in the modern era.

Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES.

Br J Haematol. 2019 Jan;184(1):45-59. doi: 10.1111/bjh.15614. Epub 2018 Nov 8. Review.

PMID:
30407610
22.

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2018 Oct 2;9(77):34641. doi: 10.18632/oncotarget.26214. eCollection 2018 Oct 2.

23.

Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity.

Preite S, Cannons JL, Radtke AJ, Vujkovic-Cvijin I, Gomez-Rodriguez J, Volpi S, Huang B, Cheng J, Collins N, Reilley J, Handon R, Dobbs K, Huq L, Raman I, Zhu C, Li QZ, Li MO, Pittaluga S, Uzel G, Notarangelo LD, Belkaid Y, Germain RN, Schwartzberg PL.

Nat Immunol. 2018 Sep;19(9):986-1000. doi: 10.1038/s41590-018-0182-3. Epub 2018 Aug 20.

24.

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.

Aue G, Sun C, Liu D, Park JH, Pittaluga S, Tian X, Lee E, Soto S, Valdez J, Maric I, Stetler-Stevenson M, Yuan C, Nakamura Y, Muranski P, Wiestner A.

J Immunol. 2018 Oct 1;201(7):1967-1974. doi: 10.4049/jimmunol.1800570. Epub 2018 Aug 13.

25.

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn IE, Wiestner A, Sun C.

Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6. No abstract available.

PMID:
29978754
26.

Human Herpes Virus 6 (HHV-6)-associated Lymphadenitis: Pitfalls in Diagnosis in Benign and Malignant Settings.

Balakrishna JP, Bhavsar T, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S.

Am J Surg Pathol. 2018 Oct;42(10):1402-1408. doi: 10.1097/PAS.0000000000001121.

27.

Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

Gong S, Crane GM, McCall CM, Xiao W, Ganapathi KA, Cuka N, Davies-Hill T, Xi L, Raffeld M, Pittaluga S, Duffield AS, Jaffe ES.

Am J Surg Pathol. 2018 Oct;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113.

28.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM.

Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.

29.

Aspergillosis, eosinophilic esophagitis, and allergic rhinitis in signal transducer and activator of transcription 3 haploinsufficiency.

Natarajan M, Hsu AP, Weinreich MA, Zhang Y, Niemela JE, Butman JA, Pittaluga S, Sugui J, Collar AL, Lim JK, Zangeneh T, Carr T, Oler AJ, Similuk M, Rosen LB, Desai JV, Freeman AF, Holland SM, Kwon-Chung KJ, Milner JD, Lionakis MS.

J Allergy Clin Immunol. 2018 Sep;142(3):993-997.e3. doi: 10.1016/j.jaci.2018.05.009. Epub 2018 May 24. No abstract available.

PMID:
29803798
30.

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH.

Haematologica. 2018 Aug;103(8):1337-1344. doi: 10.3324/haematol.2018.192492. Epub 2018 May 10.

31.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

32.

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, Lotter J, Housel S, Stetler-Stevenson M, Yuan CM, Maric I, Calvo KR, Nierman P, Hughes TE, Saba NS, Marti GE, Pittaluga S, Herman SEM, Niemann CU, Pedersen LB, Geisler CH, Childs R, Aue G, Wiestner A.

Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.

33.

Liver disturbances in activated phosphoinositide 3-kinase δ syndrome.

Ben-Yakov G, Kapuria D, Marko J, Cho MH, Pittaluga S, Kleiner DE, Koh C, Holland S, Uzel G, Heller T.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1763-1765. doi: 10.1016/j.jaip.2018.01.005. Epub 2018 Feb 16. No abstract available.

PMID:
29378322
34.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

35.

STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.

Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, Pittaluga S, Sun A, Cohen JL, Holland SM, O'Shea JJ, Uzel G, Lenardo MJ.

J Immunol. 2018 Jan 1;200(1):110-118. doi: 10.4049/jimmunol.1701133. Epub 2017 Nov 29.

36.

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2017 Aug 4;8(43):73387-73406. doi: 10.18632/oncotarget.19945. eCollection 2017 Sep 26. Erratum in: Oncotarget. 2018 Oct 2;9(77):34641.

37.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16. No abstract available.

38.

Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI.

Absinta M, Ha SK, Nair G, Sati P, Luciano NJ, Palisoc M, Louveau A, Zaghloul KA, Pittaluga S, Kipnis J, Reich DS.

Elife. 2017 Oct 3;6. pii: e29738. doi: 10.7554/eLife.29738.

39.

Re-evaluating TTF-1 immunohistochemistry in diffuse gliomas: Expression is clone-dependent and associated with tumor location.

Pratt D, Afsar N, Allgauer M, Fetsch P, Palisoc M, Pittaluga S, Quezado M.

Clin Neuropathol. 2017 Nov/Dec;36(6):263-271. doi: 10.5414/NP301047.

PMID:
28933335
40.

The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F, Pileri S, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):453-466. doi: 10.1007/s00428-017-2199-7. Epub 2017 Aug 26. Review.

PMID:
28844114
41.

Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, Quezado M.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):697-708. doi: 10.1093/jnen/nlx051.

42.

Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Rosenwald A, Wotherspoon A, Fend F.

Virchows Arch. 2017 Oct;471(4):467-489. doi: 10.1007/s00428-017-2176-1. Epub 2017 Jul 10.

PMID:
28695297
43.

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.

Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M.

N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. No abstract available.

44.

CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.

Ozen A, Comrie WA, Ardy RC, Domínguez Conde C, Dalgic B, Beser ÖF, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ.

N Engl J Med. 2017 Jul 6;377(1):52-61. doi: 10.1056/NEJMoa1615887. Epub 2017 Jun 28.

45.

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH.

Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22. No abstract available.

46.

B-cell lymphomas with discordance between pathological features and clinical behavior.

de Leval L, Copie-Bergman C, Rosenwald A, Rimsza L, Pittaluga S, Bisig B, Dirnhofer S, Facchetti F, Pileri S, Fend F, Wotherspoon A.

Virchows Arch. 2017 Oct;471(4):439-451. doi: 10.1007/s00428-017-2152-9. Epub 2017 Jun 1.

PMID:
28573510
47.

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH.

Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.

48.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

49.

DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation.

Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, Dunleavy K, Shah NN, Freeman AF.

Front Pediatr. 2017 Feb 28;5:38. doi: 10.3389/fped.2017.00038. eCollection 2017.

50.

KSHV-associated and EBV-associated Germinotropic Lymphoproliferative Disorder: New Findings and Review of the Literature.

Bhavsar T, Lee JC, Perner Y, Raffeld M, Xi L, Pittaluga S, Jaffe ES.

Am J Surg Pathol. 2017 Jun;41(6):795-800. doi: 10.1097/PAS.0000000000000823. Review.

Supplemental Content

Loading ...
Support Center